“We are pleased with the pace of progress of both trials, which in some cases have enrolled patients faster than our previous forecasts. We are seeing rapid progress with encouraging… Read More
VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) — Quark Venture LP and GF Securities today announced that they have contributed to the $12 million seed financing to launch Volastra… Read More
VANCOUVER, British Columbia, Feb. 10, 2020 /PRNewswire/ — Bold Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has received clearance from Health Canada to initiate a Phase 1b trial of… Read More
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation… Read More
SEATTLE, Feb. 06, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate… Read More
